Details of the Drug

General Information of Drug (ID: DM4LT8A)

Drug Name

Dapsone

Synonyms

Aczone; Atrisone; Avlosulfon; Avlosulfone; Avlosulphone; Avsulfor; Croysulfone; Croysulphone; DADPS; DDS; Dapson; Dapsona; Dapsonum; Diaminodifenilsulfona; Diaminodiphenylsulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dubronaz; Dumitone; Eporal; Novophone; Protogen; Sulfadione; Sulfona; Sulfonyldianiline; Sulphadione; Sulphonyldianiline; Tarimyl; Udolac; Araldite HT; D SS; Diaminodifenilsulfona [Spanish]; Diaminodiphenyl sulfone;Fatol Brand of Dapsone; Metabolite C; Orsade Brand of Dapsone; Sulfone ucb; Sumicure S; Araldite HT 976; F 1358; HT 976; HY 976; Hardener HT 976; W R 448; WR 448; ALBB-005917; AZT + Dapsone cominbation; Aczone (TN); DDS (pharmaceutical); DDS, diaphenylsulfone; DDS, pharmaceutical; DSS (VAN); Dapsoderm-X; Dapson-Fatol; Dapsona [INN-Spanish]; Dapsone (USP); Dapsone [USAN:BAN]; Dapsonum [INN-Latin];Diamino-diphenyl sulphone; Diaphenylsulfone (JAN); IN-201; Mex-America Brand of Dapsone; P-Aminophenyl sulfone; Sulfanona-mae; Sulfon-mere; Sulfona-MAE; Sulphon-mere; Bis(4-aminophenyl) sulfone; Bis(4-aminophenyl)sulfone; Bis(4-aminophenyl)sulphone; Bis(p-aminophenyl) sulfone; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl) sulfone; Di(4-aminophenyl)sulfone; Di(4-aminophenyl)sulphone; Di(p-aminophenyl) sulfone; Di(p-aminophenyl)sulphone; P,p-Diaminodiphenyl sulphone; P,p-Sulfonylbisbenzamine; P,p-Sulfonylbisbenzenamine; P,p-Sulphonylbisbenzamine; P,p-Sulphonylbisbenzenamine; P,p-Sulphonyldianiline; N, N'-Diphenyl sulfondiamide; N,N'-Diphenyl sulfondiamide; P, p'-Sulfonyldianiline; P,p'-Diaminodiphenyl sulfone; P,p'-sulfonyldianiline; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; Sulfone, 4,4'-Diaminophenyl; (4-sulfanilylphenyl)amine; 1,1'-Sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); 4,4' Diaminophenyl Sulfone; 4,4'-Dapsone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl suphone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonylbisaniline; 4,4'-Sulfonylbisbenzamine; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonyldianiline;4,4'-Sulfonyldianiline (Dapsone); 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; 4,4'-Sulphonyldianiline; 4,4'-diaminophenyl sulfone; 4,4-Diaminodifenylsulfon; 4,4-Diaminodifenylsulfon [Czech]; 4,4-Sulfonyldianiline; 4-(4-aminophenyl)sulfonylaniline; 4-Aminop henyl sulfone; 4-Aminophenyl sulfone; 4-Aminophenylsulfone; 4-[(4-aminobenzene)sulfonyl]aniline; 4-[(4-aminophenyl)sulfonyl]aniline

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]
Dermatitis herpetiformis	EB44	Approved	[1]
Leprosy	N.A.	Approved	[1]
Pemphigus vulgaris	EB40	Approved	[1]
Pneumocystis pneumonia	CA40.20	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antiinflammatory Agents

Affected Organisms

MycobacteriaMycobacterium leprae

ATC Code

D10AX05: Dapsone

D10AX: Other anti-acne preparations for topical use

D10A: ANTI-ACNE PREPARATIONS FOR TOPICAL USE

D10: ANTI-ACNE PREPARATIONS

D: DERMATOLOGICALS

J04BA02: Dapsone

J04BA: Drugs for treatment of lepra

J04B: DRUGS FOR TREATMENT OF LEPRA

J04: ANTIMYCOBACTERIALS

J: ANTIINFECTIVES FOR SYSTEMIC USE

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

248.3

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 70-80% []
Clearance: The drug present in the plasma can be removed from the body at the rate of 0.48 mL/min/kg [4]
Elimination: The drug is excreted via renal []
Half-life: The concentration or amount of drug in body reduced by one-half in 28 (range 10 - 50) hours [4]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 20.13647 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.25% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.83 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.2 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Agranulocytosis	Not Available	MPO	OTOOXLIN	[6]
Hypersensitivity	Not Available	NAA20	OTJB0VA6	[6]
-----------

Chemical Identifiers

Formula: C12H12N2O2S
IUPAC Name: 4-(4-aminophenyl)sulfonylaniline
Canonical SMILES: C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N
InChI: InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
InChIKey: MQJKPEGWNLWLTK-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2955
ChEBI ID: CHEBI:4325
CAS Number: 80-08-0
UNII: 8W5C518302
DrugBank ID: DB00250
TTD ID: D0MA9N
INTEDE ID: DR0415
ACDINA ID: D00168

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Pneumocystis carinii Dihydropteroate synthase (PC DHPS)	TT6NHYC	FOL1_PNECA	Modulator	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 2E1 (CYP2E1)_{Main DME}	DEVDYN7	CP2E1_HUMAN	Substrate	[9]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[10]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[9]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[11]
Prostaglandin G/H synthase 2 (COX-2)	DE492CE	PGH2_HUMAN	Substrate	[12]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[9]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[11]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[12]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[9]
Myeloperoxidase (MPO)	DEA3U9Y	PERM_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Arylamine N-acetyltransferase 2 (NAT2)	OTBPDQOY	ARY2_HUMAN	Biotransformations	[13]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[14]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Gene/Protein Processing	[15]
Glucose-6-phosphate 1-dehydrogenase (G6PD)	OT300SMK	G6PD_HUMAN	Drug Response	[16]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[17]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Protein Interaction/Cellular Processes	[18]
Myeloperoxidase (MPO)	OTOOXLIN	PERM_HUMAN	Drug Response	[6]
N-alpha-acetyltransferase 20 (NAA20)	OTJB0VA6	NAA20_HUMAN	Drug Response	[6]
Protein arginine N-methyltransferase 1 (PRMT1)	OTN8GTXW	ANM1_HUMAN	Gene/Protein Processing	[19]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dapsone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Lefamulin	DME6G97	Moderate	Decreased metabolism of Dapsone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[20]
-----------

Coadministration of a Drug Treating the Disease Different from Dapsone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Nateglinide	DMLK2QH	Moderate	Decreased metabolism of Dapsone caused by Nateglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[21]
Ivosidenib	DM8S6T7	Minor	Increased metabolism of Dapsone caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[22]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Dapsone caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[23]
Mitotane	DMU1GX0	Minor	Increased metabolism of Dapsone caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[22]
Methylphenobarbital	DMDSWAG	Minor	Increased metabolism of Dapsone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[22]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Dapsone caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[24]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Dapsone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[25]
Pexidartinib	DMS2J0Z	Minor	Increased metabolism of Dapsone caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[22]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Dapsone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[26]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Dapsone caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Grepafloxacin	DMGLX0T	Moderate	Decreased metabolism of Dapsone caused by Grepafloxacin mediated inhibition of CYP450 enzyme.	Bronchitis [CA20]	[28]
Secobarbital	DM14RF5	Minor	Increased metabolism of Dapsone caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[22]
Phenylbutazone	DMAYL0T	Minor	Increased metabolism of Dapsone caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[22]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Dapsone caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[29]
Aminoglutethimide	DMWFHMZ	Minor	Increased metabolism of Dapsone caused by Aminoglutethimide mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[22]
Lumacaftor	DMCLWDJ	Minor	Increased metabolism of Dapsone caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[22]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Dapsone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[30]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Dapsone caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[31]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Dapsone caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[32]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Dapsone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[33]
Griseofulvin	DMK54YG	Minor	Increased metabolism of Dapsone caused by Griseofulvin mediated induction of CYP450 enzyme.	Dermatophytosis [1F28]	[22]
Primidone	DM0WX6I	Minor	Increased metabolism of Dapsone caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Felbamate	DM1V5ZS	Minor	Increased metabolism of Dapsone caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Oxcarbazepine	DM5PU6O	Minor	Increased metabolism of Dapsone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Cenobamate	DM8KLU9	Minor	Increased metabolism of Dapsone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Phenytoin	DMNOKBV	Minor	Increased metabolism of Dapsone caused by Phenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Fosphenytoin	DMOX3LB	Minor	Increased metabolism of Dapsone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Dapsone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Phenobarbital	DMXZOCG	Minor	Increased metabolism of Dapsone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Carbamazepine	DMZOLBI	Minor	Increased metabolism of Dapsone caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Eslicarbazepine	DMZREFQ	Minor	Increased metabolism of Dapsone caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Tazemetostat	DMWP1BH	Minor	Increased metabolism of Dapsone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[22]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Dapsone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[34]
Sulfinpyrazone	DMEV954	Minor	Increased metabolism of Dapsone caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[22]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Dapsone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[35]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Dapsone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[36]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Dapsone and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[37]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Dapsone caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Saquinavir	DMG814N	Major	Decreased metabolism of Dapsone caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Dapsone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Dapsone and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Dapsone caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Dapsone caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[24]
Diltiazem	DMAI7ZV	Moderate	Decreased metabolism of Dapsone caused by Diltiazem mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[42]
Probenecid	DMMFWOJ	Moderate	Decreased elimination of Dapsone caused by Probenecid mediated competitive inhibition of renal tubular secretion.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[43]
Amobarbital	DM0GQ8N	Minor	Increased metabolism of Dapsone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[22]
Pentobarbital	DMFNH7L	Minor	Increased metabolism of Dapsone caused by Pentobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[22]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Dapsone and Porfimer Sodium.	Lung cancer [2C25]	[44]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Dapsone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[24]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Dapsone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[45]
Vemurafenib	DM62UG5	Minor	Increased metabolism of Dapsone caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[22]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Dapsone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[23]
Nitisinone	DMVS9WQ	Moderate	Decreased metabolism of Dapsone caused by Nitisinone mediated inhibition of CYP450 enzyme.	Metabolism inborn error [5C50]	[46]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Dapsone and Thalidomide.	Multiple myeloma [2A83]	[40]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Dapsone and Ocrelizumab.	Multiple sclerosis [8A40]	[47]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Dapsone caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[46]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Dapsone and Methoxsalen.	Mycosis fungoides [2B01]	[24]
Bexarotene	DMOBIKY	Minor	Increased metabolism of Dapsone caused by Bexarotene mediated induction of CYP450 enzyme.	Mycosis fungoides [2B01]	[22]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Dapsone caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[48]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Dapsone caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[49]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Dapsone and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[50]
Modafinil	DMYILBE	Minor	Increased metabolism of Dapsone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[51]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Dapsone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[52]
Prilocaine	DMI7DZ2	Major	Increased risk of methemoglobinemia by the combination of Dapsone and Prilocaine.	Pain [MG30-MG3Z]	[53]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Dapsone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[54]
Prednisone	DM2HG4X	Minor	Increased metabolism of Dapsone caused by Prednisone mediated induction of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[22]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Dapsone caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[55]
Verteporfin	DMIY6DB	Moderate	Increased risk of photosensitivity reactions by the combination of Dapsone and Verteporfin.	Psoriasis [EA90]	[23]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Dapsone caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[56]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Dapsone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[57]
Dexamethasone	DMMWZET	Minor	Increased metabolism of Dapsone caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[22]
Nafcillin	DMN9RPO	Minor	Increased metabolism of Dapsone caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[22]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Dapsone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[23]
Armodafinil	DMGB035	Minor	Increased metabolism of Dapsone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[51]
LEE011	DMMX75K	Moderate	Decreased metabolism of Dapsone caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[58]
Prednisolone	DMQ8FR2	Minor	Increased metabolism of Dapsone caused by Prednisolone mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[22]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Dapsone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[59]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Dapsone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[57]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Dapsone and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[57]
Elagolix	DMB2C0E	Minor	Increased metabolism of Dapsone caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[22]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Dapsone and Ganciclovir.	Virus infection [1A24-1D9Z]	[24]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Dapsone and Valganciclovir.	Virus infection [1A24-1D9Z]	[24]
-----------


⏷ Show the Full List of 82 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dapsone 100 mg tablet	100 mg	Oral Tablet	Oral
Dapsone 25 mg tablet	25 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Dapsone FDA Label
2	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab Dispos. 1996 Feb;24(2):164-171.
9	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
10	Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol. 2004 May 15;67(10):1831-41.
11	Drug Interactions Flockhart Table
12	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13	N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects. Skin Pharmacol Appl Skin Physiol. 2003 Nov-Dec;16(6):386-92. doi: 10.1159/000072934.
14	Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
15	Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
16	Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone. J Pharmacol Exp Ther. 1995 May;273(2):870-7.
17	Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
18	The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol. 2001 Apr;124(1):157-62. doi: 10.1046/j.1365-2249.2001.01503.x.
19	Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. Bioorg Med Chem. 2011 Jun 15;19(12):3717-31. doi: 10.1016/j.bmc.2011.02.032. Epub 2011 Feb 27.
20	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
21	Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
22	Product Information. Aczone (dapsone topical). QLT USA, Inc, Fort Collins, CO.
23	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
24	Cerner Multum, Inc. "Australian Product Information.".
25	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
26	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
27	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
28	Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
29	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
30	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
31	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
32	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
33	Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
34	Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
35	Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
36	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
37	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
38	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
39	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
40	Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
41	Olkkola KT, Palkama VJ, Neuvonen PJ "Ritonavir's role in reducing fentanyl clearance and prolonging its half-life." Anesthesiology 91 (1999): 681-5. [PMID: 10485779]
42	Abernethy DR, Egan JM, Dickinson TH, Carrum G "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans." J Pharmacol Exp Ther 244 (1988): 994-9. [PMID: 3252045]
43	Goodwin C, Sparell G "Inhibition of dapsone excretion by probenecid." Lancet 2 (1969): 884. [PMID: 4186460]
44	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
45	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
46	Canadian Pharmacists Association.
47	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
48	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
49	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
50	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
51	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
52	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
53	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
54	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
55	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
56	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
57	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
58	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
59	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.